Biscayne Pharmaceuticals Inc.

Biscayne Pharmaceuticals is developing novel drugs for cancer and other serious disorders based on analogs of growth hormone-releasing hormone (GHRH) discovered by Dr. Andrew V. Schally, Nobel laureate and renowned drug researcher. Our extensive preclinical data package demonstrates that BIS-1602 disrupts a fundamental cancer pathway. We believe that a positive outcome in one cancer type will indicate proof of concept applicable to multiple cancers and that potential acquirers will appreciate that fact. Our lead compound has inhibited the growth of many cancers (which represent 78% of all cancer deaths in 2012) in preclinical studies.